



# Tibsovo in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · IDH1-MUTATED AML / CHOLANGIOCARCINOMA

## The clinical situation

Tibsovo (ivosidenib) is an FDA-approved small-molecule inhibitor of mutant IDH1 from Servier for IDH1-mutated acute myeloid leukaemia (newly diagnosed in older/unfit patients, or relapsed/refractory) and IDH1-mutated advanced cholangiocarcinoma. Taken as an oral tablet once daily. Eligibility requires confirmation of an IDH1 mutation on tumour or bone marrow sample. Monitoring includes baseline and on-treatment ECGs (QTc), assessment for differentiation syndrome in AML, and hepatic surveillance.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist or haematologist confirms IDH1 mutation and documents a written rationale and line history.
- 2 Prescribing facility confirmed.** A Saudi tertiary centre with ECG, haematology, and hepatic-monitoring capability accepts the case.
- 3 SFDA named-patient application.** Clinical rationale, molecular report, patient reference, product details, and differentiation-syndrome surveillance plan are filed with the SFDA Drug Sector.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-controlled shipment with chain-of-custody.
- 5 Arrival & dispensing.** The hospital pharmacy releases the bottle with physician instructions for once-daily dosing; refills coordinated on a rolling monthly schedule.

## Indicative economics

**Reference US cash-pay range:** USD 29,000–33,000 per 30-day supply; drug-only reference. Reserve Meds provides a transparent delivered quote at intake.

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first dispense, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, including molecular attestation and differentiation-syndrome plan. **Logistics.** Chain-of-custody shipment coordination. **Concierge case lead.** Named point of contact through intake, first dispense, and refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Tibsovo × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/tibsovo-saudi-arabia.html](https://reservemed.com/access-guides/tibsovo-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team